PBMC PAR levels in healthy volunteers and patients with cancer after ex vivo ABT-888 treatment.

<p>(A) Pooled PBMCs from healthy volunteers were treated ex vivo for 2 h with increasing concentrations of ABT-888. PAR levels were then determined by PAR immunoassay and normalized (100%) to the vehicle-treated control. Error bars represent standard deviations from three separate experiments. PAR levels were compared between (B) PBMCs from four healthy volunteers (HV) and four patients (Pt) with cancer and (C) 40 individual healthy volunteers. PBMC samples were treated ex vivo with 0.21 µM ABT-888 (the target clinical exposure) for 2 h and PAR levels are reported relative to vehicle-treated controls (100%). Dashed line, 50% reduction.